Walvax Biotechnology (SHE:300142) posted first-half attributable net profit of 43.2 million yuan, down 75% from 170.6 million yuan the previous year.
Earnings per share went up to 0.0273 yuan from 0.1066 yuan, according to a Tuesday filing with the Shenzhen bourse.
The pharmaceutical company's operating revenue declined 19% year over year to 1.15 billion yuan from 1.43 billion yuan.
Shares of the company slipped 1% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments